Intercure Ltd. (INCR) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for INCR in the last 30 days. The most recent was published Sep 8, 2026.
Financial highlights
Full financials- Revenue, FY2025
- ILS 270.20M
- Revenue growth
- +13.1%
- Net income, FY2025
- -ILS 35.71M
- Net margin
- -13.2%
- Free cash flow, FY2025
- ILS 13.29M
- Cash
- ILS 46.47M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks170%
2026-05-102026-11-01
Mix1090d
- SEC Filings6(60%)
- Other3(30%)
- Insider1(10%)
Latest news
25 items- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- PRInterCure Regains Compliance with Nasdaq Minimum Bid Price RequirementNEW YORK and HERZLIYA, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") announced today that it received written confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement"). The confirmation follows a written notification received by the Company from Nasdaq on September 1, 2026, indicating that the Company’s ordinary shares were subject to delisting from The Nasdaq Global Market (the "Delisting Notice"). As previously disclose
- SECAmendment: SEC Form 6-K/A filed by Intercure Ltd.6-K/A - Intercure Ltd. (0001857030) (Filer)
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Cohen Amos4 - Intercure Ltd. (0001857030) (Issuer)
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- PRInterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect DamagesCompany intends to accelerate the rehabilitation of Canndoc’s flagship Nir Oz facility, supporting a return to full production and the Company’s expansion in the growing German medical cannabis market NEW YORK and HERZLIYA, Israel, Aug. 24, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company"), today announced that it has reached a final settlement with the Israeli Tax Authorities and Compensation Fund regarding the Company’s claim for indirect damages resulting from the October 7, 2023 attacks and the subsequent war. Under the final settlement, aggregated compensation for the indirect damage covered by the claim has been agreed at a total of
- SECSEC Form D filed by Intercure Ltd.D - Intercure Ltd. (0001857030) (Filer)
- PRInterCure Ltd. Announces 1-for-5 Reverse Share SplitStrategic Action Aimed at Regaining Compliance with Nasdaq’s Minimum Bid Price Requirement and Protecting Continued Listing Status NEW YORK and HERTZLIYA, ISRAEL, Aug. 19, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (the "Company" or "InterCure") (NASDAQ:INCR), today announced that it intends to effect a one-for-five reverse split (the "Reverse Share Split") of the Company’s ordinary shares, no par value per share, (the "Ordinary Shares"). The Ordinary Shares will continue to trade on the Nasdaq Global Market under the existing symbol "INCR", and will begin trading on a split-adjusted basis when the market opens on August 24, 2026. The new CUSIP number for the Ordinary Shares following the Re
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- SECAmendment: SEC Form 6-K/A filed by Intercure Ltd.6-K/A - Intercure Ltd. (0001857030) (Filer)
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- PRInterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds●The funding includes investments commitments from key shareholders of the Company, including the Company’s CEO Alexander Rabinovich, as well as leading pharma-focused hedge funds, including Bennu Pharma Fund Ltd., managed by Mr. Ori Hershkovitz. ●The funding may increase to NIS 54 million to support the Company’s global expansion, including growing demand in Germany and opportunities in regulated U.S. medical cannabis markets. NEW YORK & HERZLIYA, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), today announced that, further to the Company’s prior reports regarding growing demand in Germany and opportunitie
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- PRInterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico AcquisitionFirst Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and Evaluates Opportunities in Regulated U.S. Medical Cannabis Markets. NEW YORK and HERZLIYA, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") today announced the successful completion of the first tranche of its acquisition of Botanico Ltd. ("Botanico"), also known as ISHI, an Israeli cannabis technology and brand company. Following the recent U.S. federal rescheduling of certain state-licensed medical cann
- SECSEC Form 6-K filed by Intercure Ltd.6-K - Intercure Ltd. (0001857030) (Filer)
- PRInterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash FlowThe Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 million in positive operating cash flow, reflecting strong resilience and consistent profitability, with a twelfth consecutive half-year of positive Adjusted EBITDA, as the Company continues to recover from the impact of the October 7, 2023 events NEW YORK and HERZLIYA, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company"), today announced its financial and operating results for 2025. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted. FY2025 Financial Highlights and Milest
- SECSEC Form 20-F filed by Intercure Ltd.20-F - Intercure Ltd. (0001857030) (Filer)
- INSIDERSEC Form 3 filed by new insider Rabinovich Alexander3 - Intercure Ltd. (0001857030) (Issuer)
- INSIDERSEC Form 3 filed by new insider Michelson Lennie Grinbaum3 - Intercure Ltd. (0001857030) (Issuer)
- INSIDERSEC Form 3 filed by new insider Granot Alon Shmuel3 - Intercure Ltd. (0001857030) (Issuer)
- INSIDERSEC Form 3 filed by new insider Salton David3 - Intercure Ltd. (0001857030) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cohen Amos3 - Intercure Ltd. (0001857030) (Issuer)
INCR FAQ
10 questionsWhat does Intercure Ltd. do?
InterCure Ltd, together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.What is the latest news on INCR?
Quantisnow has not tracked any new filings, ratings or press releases for INCR in the last 30 days. The most recent wire item was published on September 8, 2026.What is INCR revenue?
Intercure Ltd. (INCR) reported ILS 270.20M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 13.1% from the year before.Is INCR profitable?
No. Intercure Ltd. reported a net loss of ILS 35.71M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does INCR have?
Intercure Ltd. reported ILS 46.47M in cash and cash equivalents and ILS 59.46M of debt on its most recent balance sheet in SEC filings.Where does INCR stock trade?
Intercure Ltd. (INCR) is listed on NASDAQ.What sector and industry is INCR in?
Intercure Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about INCR?
Across the last 1 analyst actions on Intercure Ltd., there was 1 upgrade and 0 downgrades. The most recent action was from Canaccord Genuity: Buy with a $13.00 price target on 2022-05-18. Recent price targets cluster around $13.00.What companies are similar to INCR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare INCR side-by-side with any of them on Quantisnow.How can I track INCR on Quantisnow?
Quantisnow aggregates Intercure Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INCR to receive live email and push alerts on every new disclosure.